Key Events This Week
27 Jul: Stock opens at Rs.150.20, modest gain of 1.04%
28 Jul: Downgrade to Strong Sell announced; stock surges 13.65% to Rs.170.70
29 Jul: Valuation concerns highlighted; stock declines 2.93% to Rs.165.70
30 Jul: Upgrade to Sell rating; stock falls 3.05% to Rs.160.65
31 Jul: Week closes with a 1.21% gain at Rs.162.60

Sanjivani Paranteral Ltd Upgraded to Sell on Improved Valuation and Financial Metrics
2026-07-30 08:01:53Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 29 July 2026. This revision reflects a notable improvement in valuation metrics alongside a mixed financial trend and technical outlook. Despite recent quarterly setbacks, the company’s fair valuation and operational efficiency have prompted a more favourable stance from analysts.
Read full news article
Sanjivani Paranteral Ltd Downgraded to Strong Sell Amid Valuation and Financial Concerns
2026-07-29 08:02:31Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 28 July 2026. This revision reflects a combination of deteriorating financial trends, expensive valuation metrics, weakening technical indicators, and a reassessment of the company’s overall quality. The downgrade comes despite a recent sharp rally in the stock price, which surged 13.65% on the day following the announcement.
Read full news article
Sanjivani Paranteral Ltd Valuation Shifts Signal Price Attractiveness Challenges
2026-07-29 08:00:32Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade to Strong Sell. Despite a recent surge in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have moved into expensive territory, raising questions about its price attractiveness relative to historical and peer benchmarks.
Read full news article
Sanjivani Paranteral Ltd is Rated Sell
2026-07-26 10:10:40Sanjivani Paranteral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 July 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Sanjivani Paranteral Ltd Rating Upgraded to Sell Amid Mixed Financial and Technical Signals
2026-07-15 08:01:41Sanjivani Paranteral Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing financial challenges. The revision follows a detailed reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals, highlighting both the company’s strengths and areas of concern within the Pharmaceuticals & Biotechnology sector.
Read full news article
Sanjivani Paranteral Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals
2026-07-08 08:02:23Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 7 July 2026. This revision reflects deteriorating financial performance, bearish technical indicators, and valuation concerns, signalling heightened risk for investors amid a challenging market environment.
Read full news article







